Cytogen Corporation And Royal Philips Electronics N.V. Demonstrate PROSTASCINT(R) Image Acquisition And Processing Tools That Improve Efficiency And Reduce Imaging Time

PRINCETON, N.J., June 8 /PRNewswire-FirstCall/ -- Cytogen Corporation (Nasdaq: CYTO - News) and Royal Philips Electronics (NYSE: PHG; AEX: PHI) today announced the presentation of data demonstrating significantly improved resolution and quality of PROSTASCINT® (capromab pendetide) images through the application of Philips' unique Astonish image processing tools. Results were presented at the 53rd Society of Nuclear Medicine (SNM) annual meeting in San Diego, CA on June 5, 2006.

Back to news